NCT05203380 - Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

March 10, 2023

Study Completion Date

March 10, 2023

Conditions

Moderate-to-severe Atopic Dermatitis

Interventions

DRUG

dupilumab

Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)

Trial Locations (10)

DermAssociates, LLC, Rockville

Virginia Clinical Research, Inc., Norfolk

National Allergy and Asthma Research, LLC, North Charleston

Skin Care Physicians of Georgia, Macon

Pediatric Skin Research, LLC, Coral Gables

Skin Research of South Florida, LLC, Miami

Clinical Research Center of Alabama, LLC, Birmingham

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Texas Dermatology and Laser Specialists, San Antonio

Arizona Allergy & Immunology Research, Gilbert